GlassScriptPhysician profile
Cathy J Berry
NPI 1144209644
$3,103.32
in general payments reported to CMS, 2019-2025
31 companies · $438 in 2025
The $438 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $386 · 2021: $433 · 2022: $572 · 2023: $511 · 2024: $156 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.37 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $332.29 | 2019-2025 | |
| Coopersurgical, INC. | $308.55 | 2019-2022 | |
| Gilead Sciences, INC. | $189.05 | 2022-2025 | |
| Amgen INC. | $169.99 | 2019-2025 | Evenity |
| Mayne Pharma Commercial LLC | $132.27 | 2021-2023 | |
| Therapeuticsmd, INC. | $124.61 | 2019-2022 | |
| Astellas Pharma US INC | $103.85 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $83.56 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $79.90 | 2020-2023 | Slynd |
| Agile Therapeutics, INC. | $78.52 | 2021-2022 | |
| Biogen, INC. | $73.45 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $68.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.84 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $52.01 | 2022 | |
| Shield Therapeutics INC | $49.29 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $48.09 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $42.12 | 2019-2020 | |
| Roche Diagnostics Corporation | $38.12 | 2019-2021 | |
| Smith+Nephew, INC. | $34.39 | 2019-2022 | |
| Covidien LP | $32.49 | 2019 | |
| Allergan, INC. | $32.14 | 2019 | |
| Evofem Biosciences, INC. | $24.67 | 2021 | |
| Scynexis, INC. | $23.27 | 2022 | |
| Olympus America INC. | $21.28 | 2023 | |
| Organon LLC | $20.43 | 2024 | |
| Alkermes, INC. | $20.30 | 2021 | |
| Millicent US INC | $17.71 | 2024 | Femring, Intrarosa |
| Lupin INC. | $16.34 | 2020 | |
| Medicem INC. | $14.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.